Wedbush Raises Price Target on Apogee Therapeutics (APGE)

Core Insights - Apogee Therapeutics Inc. (NASDAQ:APGE) is identified as one of the 10 most shorted biotech stocks to consider for investment according to hedge funds [1] - Wedbush has raised its price target for Apogee from $90 to $95, maintaining an Outperform rating, indicating a potential upside of 30% from current levels [1] Financial Performance - For FY25, Apogee reported a net loss of $255.8 million, an increase from a net loss of $182.1 million in the previous year [3] - The company has a cash runway extending into the second half of 2028, positioning it well for future developments [3] Clinical Developments - Apogee reaffirmed its guidance on the 52-week Phase 2 APEX study data, with induction data for the dose-ranging trial expected in Q2 2026 [2] - The Phase 3 trials are anticipated to commence in the second half of the year, with further developments expected from APG279 [2] - Significant progress has been made in the pipeline, including positive results from the APEX Phase 2 Part A trial and proof-of-concept data from a Phase 1b trial in asthma [3] Product Pipeline - Apogee is focused on developing biologics for inflammatory and immune diseases, including atopic dermatitis, asthma, and eosinophilic esophagitis [4][5] - The existing pipeline includes multiple candidates such as APG777, APG279, APG990, APG333, and APG808, all at various stages of clinical trials [5]